Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IntercureINCR -0.09%67 Gross Margin % is -3.59% as of Dec. 2025. GuruFocus rates INCR with a GF Score™ of 67/100 and a GF Value™ of $6.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 939 Drug Manufacturers companies, Intercure ranks worse than 94.78% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Intercure's Gross Profit for the
six
months ended in Dec. 2025 was $-1.68 Mil. Intercure's Revenue for the
six
months ended in Dec. 2025 was $46.63 Mil. Therefore, Intercure's Gross Margin % for the quarter that ended in Dec. 2025 was -3.59%.
Warning Sign:
Intercure Ltd gross margin has been in long-term decline. The average rate of decline per year is -26.5%.
The historical rank and industry rank for Intercure's Gross Margin % or its related term are showing as below:
INCR'
s Gross Margin % Range Over the Past 10 Years
Min: 12.28 Med: 29.56 Max: 49.17
Current: 12.28
During the past 13 years, the highestGross Margin % of Intercure was 49.17%. The lowest was 12.28%. And the median was 29.56%.
INCR's Gross Margin % is ranked worse than 94.78% of 939
companies
in the Drug Manufacturers industry
Industry Median: 48.55
vs INCR: 12.28
Intercure had a gross margin of -3.59% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Intercure was -26.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Intercure had a gross margin of -3.59% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Intercure Gross Margin % Related Terms
Intercure Gross Margin % Historical Data
* Premium members only.
The historical data trend for Intercure's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INCR vs CTOR, ZYBT, TLPH: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercure Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intercure's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Intercure's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Intercure (INCR) has a Gross Margin % of -3.59% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Intercure and its competitors. Over the past decade, Intercure's Gross Margin % has ranged from 12.28 to 49.17. According to the industry distribution chart, Intercure ranks #890 out of 939 companies in the Drug Manufacturers industry, placing it in the top 94.8%.
Is Intercure's Gross Margin % too high?
Intercure's current Gross Margin % is -3.59%. Over the past 10 years, this metric has ranged from a low of 12.28 to a high of 49.17. Based on the distribution chart, Intercure ranks #890 out of 939 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Intercure has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intercure's Gross Margin % compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #890 out of 939 companies for Gross Margin %. This places Intercure in the lower half of its industry. The industry median Gross Margin % is 48.55. Historically, Intercure's own Gross Margin % has ranged from 12.28 to 49.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.55, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Intercure and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intercure's current Gross Margin % is -3.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.18, compared to a current price of $5.33 — trading 13.8% below its estimated fair value. The current Gross Margin % is -3.59%. Intercure's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Intercure (INCR), the current Gross Margin % is -3.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intercure (INCR) Overvalued in 2026?
Based on GuruFocus' analysis, Intercure stock appears to be undervalued.
The current stock price of $5.33 is trading 13.8% below its estimated GF Value™ of $6.18.
GuruFocus considers Intercure to be Modestly Undervalued.
Key valuation signals for INCR:
Gross Margin %: -3.59%
GF Value™: $6.18 vs. price of $5.33 (13.8% below fair value)
No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
67GF Score
Get the complete analysis for INCR
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCR has been successfully added to your 
